Bronstein, Gewirtz & Grossman, LLC Investigating Possible Securities Law Violations At MELA Sciences, Inc.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of MELA Sciences, Inc.(“MELA” or the “Company”) (NASDAQ:MELA - News), concerning whether the company has violated federal securities laws by issuing false and misleading statement to shareholder concerning MELA’s melanoma detection device MelaFind.
The U.S. Food and Drug Administration cast doubt on MelaFind, stating that “[t]he FDA review team has significant concerns this device has not been studied adequately for its current indication for use and therefore puts the health of the public at risk.” In particular, FDA reviewers were concerned about the device’s accuracy rate and have recommended that an additional study be conducted. On this news shares of medical device maker MELA closed down over 54% for the day, to $2.92 per share.
If you are aware of any facts relating to this investigation, or purchased shares of MELA, you can assist this investigation by contacting either Peretz Bronstein or Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.
Our primary expertise is the aggressive pursuit of litigation claims on
behalf of our clients. In addition to representing institutions and
other investor plaintiffs in class action security litigation, the
firm’s expertise includes general corporate work, private securities
offerings, and securities arbitration.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV